Edition:
United States

People: INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

8.90USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$8.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
167,571
52-wk High
$15.01
52-wk Low
$8.70

Tambi, Brian 

Mr. Brian Tambi serves as Independent Director of Insys Therapeutics, Inc. Brian Tambi has served on our Board since November 2010. From August 2007 until the November 2010, Mr. Tambi served as a director of Insys Pharma. Mr. Tambi has served as a member of the Board of Directors of Akorn, Inc., a publicly traded specialty pharmaceutical company, since June 2009. Since forming the company in January 2006, Mr. Tambi has served as the Chairman of the Board, President and Chief Executive Officer of Antrim Pharma (formerly BrianT Laboratories LLC), a pharmaceutical company currently focused on developing, manufacturing and marketing combinations of leading single agent drugs and delivery systems. From 1995 to January 2007, Mr. Tambi served as the Chairman, President and Chief Executive Officer of Morton Grove Pharmaceuticals, Inc. Prior to Morton Grove, Mr. Tambi served as President of Ivax North American Pharmaceuticals and as a member of the board of directors of Ivax Corporation (acquired by Teva), a publicly traded pharmaceutical company. Mr. Tambi also served as Chief Operating Officer of Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Company, Ltd. Mr. Tambi also held executive positions at Lyphomed, Inc. and Bristol-Myers Squibb. Mr. Tambi earned his MBA in International Finance & Economics and his B.S. in Corporate Finance from Syracuse University.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 266,428
Fiscal Year Total, USD 266,428

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --